Zhou and his researchers investigated the therapeutic effect of trametinib in combination with oHSV in KRAS and BRAF mutant colorectal cancer, and they found that this combination therapy not only inhibited the expression of START1 mRNA and PKR in cancer cells, but also reduced the phosphorylation in BRAFwt/KRAS mutant tumour cells, which in turn facilitated the replication of oHSV, and enhanced the anti-tumour effect [29]. Here, KRAS is linked to neoplasm.